Jeff Martin
Stock Analyst at Roth MKM
(2.88)
# 2,413
Out of 4,831 analysts
65
Total ratings
68.75%
Success rate
16.74%
Average return
Main Sectors:
Stocks Rated by Jeff Martin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PERI Perion Network | Upgrades: Buy | $9 → $14 | $11.61 | +20.59% | 8 | May 14, 2025 | |
| OSIS OSI Systems | Maintains: Buy | $224 → $245 | $228.46 | +7.24% | 16 | May 2, 2025 | |
| BGSF BGSF, Inc. | Maintains: Buy | $12 → $9 | $4.06 | +121.67% | 1 | Mar 20, 2025 | |
| NVEE NV5 Global | Maintains: Buy | $27 → $28 | $18.97 | +47.60% | 7 | Feb 21, 2025 | |
| BBSI Barrett Business Services | Maintains: Buy | $43 → $45 | $41.85 | +7.52% | 5 | Nov 7, 2024 | |
| HCKT The Hackett Group | Maintains: Buy | $29 → $30 | $25.61 | +17.14% | 6 | Nov 5, 2024 | |
| BWMN Bowman Consulting Group | Maintains: Buy | $47 → $43 | $25.55 | +68.30% | 5 | Aug 8, 2024 | |
| FC Franklin Covey Co. | Reiterates: Buy | $50 | $23.41 | +113.58% | 7 | Jun 27, 2024 | |
| NSP Insperity | Maintains: Buy | $144 → $147 | $69.00 | +113.04% | 8 | Apr 27, 2023 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | $5,760 | $1.30 | +442,976.92% | 2 | Nov 15, 2017 |
Perion Network
May 14, 2025
Upgrades: Buy
Price Target: $9 → $14
Current: $11.61
Upside: +20.59%
OSI Systems
May 2, 2025
Maintains: Buy
Price Target: $224 → $245
Current: $228.46
Upside: +7.24%
BGSF, Inc.
Mar 20, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $4.06
Upside: +121.67%
NV5 Global
Feb 21, 2025
Maintains: Buy
Price Target: $27 → $28
Current: $18.97
Upside: +47.60%
Barrett Business Services
Nov 7, 2024
Maintains: Buy
Price Target: $43 → $45
Current: $41.85
Upside: +7.52%
The Hackett Group
Nov 5, 2024
Maintains: Buy
Price Target: $29 → $30
Current: $25.61
Upside: +17.14%
Bowman Consulting Group
Aug 8, 2024
Maintains: Buy
Price Target: $47 → $43
Current: $25.55
Upside: +68.30%
Franklin Covey Co.
Jun 27, 2024
Reiterates: Buy
Price Target: $50
Current: $23.41
Upside: +113.58%
Insperity
Apr 27, 2023
Maintains: Buy
Price Target: $144 → $147
Current: $69.00
Upside: +113.04%
Galmed Pharmaceuticals
Nov 15, 2017
Initiates: Buy
Price Target: $5,760
Current: $1.30
Upside: +442,976.92%